After the Bell
Before the Bell
Jim Cramer's Daily Booyah
Winners & Losers
AVEO Pharmaceuticals (AVEO) stock is surging in mid-morning trading on Monday after the company said it secured a licensing agreement for its renal cell carcinoma treatment in Europe.
Exelixis plans to seek expanded approval for Cometriq to treat kidney cancer in early 2016.
Trade-Ideas LLC identified AVEO Pharmaceuticals (AVEO) as a "dead cat bounce" (down big yesterday but up big today) candidate
Trade-Ideas LLC identified AVEO Pharmaceuticals (AVEO) as a "perilous reversal" (up big yesterday but down big today) candidate
©1996-2016 TheStreet, Inc. All rights reserved.
Action Alerts PLUS is a registered trademark of TheStreet, Inc.